Compare ARCT & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | CNTN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.8M | 185.3M |
| IPO Year | 2019 | 2022 |
| Metric | ARCT | CNTN |
|---|---|---|
| Price | $7.26 | $2.77 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $24.11 | N/A |
| AVG Volume (30 Days) | 439.6K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $2.14 |
| 52 Week High | $24.14 | $5.27 |
| Indicator | ARCT | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 46.09 |
| Support Level | $6.79 | $2.14 |
| Resistance Level | $7.93 | $3.80 |
| Average True Range (ATR) | 0.43 | 0.31 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 37.50 | 19.83 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.